Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

April 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.

A rare disease, also known as an "orphan disease," refers to diseases with relatively low prevalence rates.

Advanced gastrointestinal cancer patients continue to test dosages with the novel T-cell engager, CDH17 X CD3 cabotamig (ARB202).

April 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.

On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.

FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.

On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.

Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.

Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.